Cytek Biosciences (CTKB) EBIT Margin (2020 - 2026)
Cytek Biosciences (CTKB) posted EBIT Margin of 41.83% for Q1 2026, down 364.7% on a QoQ basis from 9.0% in Q4 2025, and down 571.0% year-over-year from 8.88% in Q1 2025.
Cytek Biosciences (CTKB) EBIT Margin (2020 - 2026) Analysis & Trends
Cytek Biosciences' EBIT Margin history runs 7 years deep, the most recent figure standing at 41.83% for Q1 2026.
- Quarterly EBIT Margin fell 571.0% year-over-year to 41.83% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.49% (down 892.0% YoY) and the FY2025 annual result came in at 20.04%, down 980.0% from the prior year.
- EBIT Margin was 41.83% for Q1 2026 at Cytek Biosciences, down from 9.0% in the prior quarter.
- Across five years, EBIT Margin topped out at 5.2% in Q4 2024 and bottomed at 41.83% in Q1 2026.
- A 5-year average of 14.31% and a median of 13.38% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin sank 2607 bps — and 2024, when it jumped 886 bps.
- Cytek Biosciences' EBIT Margin stood at 0.17% in 2022, then sank by 235 bps to 0.24% in 2023, then jumped by 2308 bps to 5.2% in 2024, then plunged by 273 bps to 9.0% in 2025, then plunged by 365 bps to 41.83% in 2026.
- Business Quant data shows CTKB's EBIT Margin at 41.83% in Q1 2026, 9.0% in Q4 2025, and 17.58% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn | -41.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.83% |
| Dec 31, 2025 | -9.00% |
| Sep 30, 2025 | -17.58% |
| Jun 30, 2025 | -23.30% |
| Mar 31, 2025 | -36.12% |
| Dec 31, 2024 | 5.20% |
| Sep 30, 2024 | -8.25% |
| Jun 30, 2024 | -18.29% |
| Mar 31, 2024 | -23.93% |
| Dec 31, 2023 | -0.24% |
| Sep 30, 2023 | -13.38% |
| Jun 30, 2023 | -18.37% |
| Mar 31, 2023 | -32.79% |
| Dec 31, 2022 | 0.17% |
| Sep 30, 2022 | 3.36% |
| Jun 30, 2022 | -2.22% |
| Mar 31, 2022 | -6.72% |
| Dec 31, 2021 | 3.39% |
| Sep 30, 2021 | 8.43% |
| Jun 30, 2021 | 12.53% |